AT:SPL Starpharma Holdings Limited

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia and Canada. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel that is in Phase I clinical trial for breast, prostate, lung, and ovarian tumor. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol SPHRF.

This company has ADRs that trade in the U.S. as the symbol SPHRY.This company has cross-listed shares that trade in the U.S. as the symbol SPHRF.

0.49 AUD
As of 03/24/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  09/26/2000
Stock exchange:    Asx - All Markets
Exchange country:   Australia
Market cap:   315,769,088 AUD
Current dividend yield:   0.00%
Sedol:      6291596

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy